{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059457","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.541837+00:00","generated_at":"2026-06-02T04:57:30.464563+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CytoSorbents Q1 product sales up 14% to $9.0M; gross margin expands to 76%","bullets":["Product sales $9.0M, +14% YoY from $7.9M and +22% sequentially from Q4 2023 ($7.3M).","Product gross margins 76% (excl. $304K one-time adjustment), up from 68% in Q1 2023.","Total revenue $9.8M (+4% YoY) as grant income fell 48% to $0.8M on completion of prior grants.","Plans FDA De Novo and Health Canada submissions for DrugSorb-ATR in Q3 2024; STAR-T data presented at AATS.","Cash $10.1M (incl. $1.5M restricted) expected to fund operations into Q4 2024; seeking non-dilutive financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059457","json":"https://secwatch.observer/filing/0001104659-24-059457.json","markdown":"https://secwatch.observer/filing/0001104659-24-059457.md","text":"https://secwatch.observer/filing/0001104659-24-059457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924059457/0001104659-24-059457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924059457/tm2414028d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:57:30.464563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86be61befea2ff581598fa51340e2fbff38d74d4","claim":"Cytosorbents Corp reported the quarter ended March 31, 2024 results: revenue $9.8 million.","evidence_excerpt":"$7.9 million in Q1 2023, an increase of 14%, and up 22% sequentially from $7.3 million in Q4 2023 · Total revenue, including product sales and grant income, for Q1 2024 was $9.8 million, an increase of 4% compared to $9.4 million in Q1 2023 · Q1 2024 product gross margins increased to approximately 76%, (excluding the impact of a one-time,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924059457/0001104659-24-059457-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$9.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}